Iovance Biotherapeutics Reports 66% Revenue Growth to $99.3 Million in Latest Quarter

Iovance Biotherapeutics, Inc. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenue of $99.3 million, a 66% increase from $59.9 million in the same quarter of the previous year. This growth was primarily driven by a substantial rise in product sales, particularly from its flagship therapy, Amtagvi® (lifileucel), which accounted for $90.7 million in revenue, up 68% year-over-year. Proleukin® (aldesleukin) also contributed to the revenue increase, with sales rising 46% to $8.6 million.

In terms of profitability, Iovance reported a net loss of $47.3 million for the quarter, a significant reduction from the $111.7 million loss recorded in the same period last year, marking a 58% improvement. For the first half of 2026, the net loss was $126.4 million, down 45% from $227.8 million in the first half of 2025. The decrease in net loss was attributed to increased sales of both Amtagvi® and Proleukin®, alongside a reduction in costs associated with research and development and cost of sales.

Operationally, Iovance has made strategic advancements, including the successful launch of Amtagvi® in the U.S. and its recent marketing authorization in Australia. The company is also pursuing additional approvals in the UK and EU, with a resubmission of its marketing authorization application expected in 2026 or 2027. The company’s manufacturing capabilities have been enhanced through the transition to its own facility, the Iovance Cell Therapy Center (iCTC), which is designed to support the production of TIL therapies for thousands of patients annually.

As of June 30, 2026, Iovance reported $303.7 million in cash, cash equivalents, and short-term investments, providing a solid liquidity position to support ongoing operations and clinical programs. The company anticipates continued investment in its commercial activities and clinical trials, particularly for its ongoing studies in advanced melanoma and non-small cell lung cancer. Looking ahead, Iovance expects to maintain its focus on expanding the market presence of Amtagvi® and advancing its pipeline of TIL therapies, while managing operational costs to improve financial performance further.